![[Imagem: ce5c68eb256b21e50c2b3ffc66abb054.jpg]](https://www.img.in.th/images/ce5c68eb256b21e50c2b3ffc66abb054.jpg)
Novavax and the Institute ofShaolinIndian Serum Submit documents to the World Health Organization approving the use of COVID-19 hybrid nanoparticles based on Novavax proteins are an extraordinary event.
September 27, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company that develops and markets a new generation vaccine for serious infectious diseases. The Indian Serum Institute (SII), along with its partners, has announced that it has been submitted to the World Health Organization (WHO) for approval of a vaccine against COVID-19. Protein-based hybrid nanoparticles with the Novavax Matrix-M immun Emergency Immunomodulator (EUL).
This WHO submission follows on from the fact that both parties have previously submitted documents to the Ministry of Drug Control in India (DCGI).
"Submitting WHO documents to approve the use of COVID-19." Protein-Based Types in Need This is a significant step forward in accelerating access to and promoting the equitable distribution of vaccines to countries in need of vaccines worldwide, "said Stanley C. Erck, President and CEO of Novavax.
"This is another major breakthrough in Novavax's transformation into a global commercial vaccine company." It also reinforces the value of global collaboration and the need for a diverse approach to help manage the epidemic. "
The WHO approval of the EUL will allow companies to export vaccines to countries in the COVAX facility, which is designed for even distribution of vaccines and distribution to countries. Last month, SII and Novavax met all eligibility requirements for regulators in India, Indonesia and the Philippines.
start thinking about company vaccines From pre-clinical, clinical research data to chemical, manufacturing and control data.